Table 1.
Basal characteristics of the study population, duration of pain, severity of PD and pharmacological treatment
| Sex | Agea (years) | Duration of paina (years) | UPDRS (3) scorea | UPDRS (1–4) scorea | H and Yb score | Levodopaa,c treatment (mg) | Antidepressants (n) | Anxiolytics/sedatives (n) |
|---|---|---|---|---|---|---|---|---|
| Females (n = 28) | 66.7/66.5 (60/73) | 6.5/4 (1/13) | 23.3/23 (10/37) | 36.3/36 (19/60) | 2 (0/3) | 634/562 (300/1140) | 6 | 23 |
| Males (n = 16) | 62.8/64.5 (54/69) | 4.8/4 (2/10) | 20.4/16.5 (12/36) | 34.5/32.5 (24/49) | 1.5 (0/3) | 768/758 (350/1205) | 2 | 16 |
| Total | 65.3/66 (59/73) | 5.8/4.0 (1.4/12) | 22.2/20 (10/36) | 36.3/35.5 (21/60) | 2 (0/3) | 682/650 (300/1205) | 8 | 39 |
Notes:
a
Values are given as mean/median (10/90th percentiles);
b
median;
c
LED levodopa equivalent doses, according to Tomlinson et al.37
Abbreviations: PD, Parkinson’s disease, UPDRS, Unified Parkinson’s Disease Rating Scale; H and Y, Hoehn and Yahr scale.